key: cord-0924115-245tklih authors: Montecucco, Fabrizio; Nathoe, Hendrik title: How to manage the abundant COVID‐19 submissions to a peer‐reviewed Scientific Journal date: 2021-04-13 journal: Eur J Clin Invest DOI: 10.1111/eci.13569 sha: d288b68430b5c29ed86ad9db5e2a01583144df29 doc_id: 924115 cord_uid: 245tklih In January 2020, both authors became Editors of the peer-reviewed European Journal of Clinical Investigation (EJCI). After one year, we feel it is time for a first balance of our activities. The COVID-19 pandemic deeply impacted not only on the editorial work, but also in all our professional and private lives. As Medical Doctors, every day we were involved in patients' care during this pandemic. As new Scientific Editors, we not only received a huge amount of COVID-19-related submissions (N=195), but also non-COVID-19 submissions increased tremendously (N=1101). multiple rounds of revisions. Fortunately, authors inclined at publishing in a fast track mode, thereby completing the revisions conveniently. So, despite these extra revisions we were able to make final decisions on time. We finally decided to compose a COVID-19 Special Issue, highlighting together the clinical and translational knowledge established from European countries firstly affected by the pandemic, such as Italy. The goal of the Special Issue was to share relevant information potentially helpful to other countries affected in a later stage or to fight the next COVID-19 waves. 6-8 Our conclusion is that after one year, we still have big scientific gaps on the COVID-19 pandemic and we often do not know how to manage patients suffering from COVID-19 with multiple comorbidities. Several unmet needs remain to be addressed, and our journal is widely open to all scientific contributions clarifying these issues. In the meantime, considering the non-COVID scientific production of EJCI, we attempted at highlighting new ESC guidelines in cardiovascular diseases, with the contribution of key opinion leaders. 9-11 Finally, we attempted at increasing the acceptance of basic research submissions, with particular interest for both cancer and cardiovascular domains. We are in debt with reviewers, editorial office, deputy editors and section editors for their great work for the journal. We acknowledge at the End of this Editorial and on the website of EJCI (https://onlin elibr ary.wiley.com/ journ al/13652362) the full list of colleagues who served as a reviewer for EJCI in 2020 [doi: 10.1111/eci.13621]. We are very grateful to their critical support and useful comments. Facing the pandemic with its complexities in 2020, we better learned to teach, meet, and manage scientific issues and collaborations from a remote mode. In retrospect, we are more than satisfied with the enormous amount of work that had been done by our editorial board in 2020. We wish our readers and collaborators a healthy future with hopefully some onsite meetings in the second half of 2021. Please, keep in mind that EJCI is a scientific space open to your commentaries, controversies, ideas and original research. Do not forget to submit your precious work to EJCI in order to improve knowledge and patient care! The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm Global perspective of COVID-19 epidemiology for a full-cycle pandemic QTc evaluation in COVID-19 patients treated with chloroquine/ hydroxychloroquine High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection Novel insight from the first lung transplant of a COVID-19 patient SARS-CoV-2 outbreak and lockdown in a Northern Italy hospital. Comparison with Scandinavian nolockdown country COVID-19, internists and resilience: the north-south Italy outbreak Reorganization of a large academic hospital to face COVID-19 outbreak: The model of Parma What is new in the 2020 ESC NSTE-ACS guidelines Repurposing colchicine to combat residual cardiovascular risk: the LoDoCo2 trial Atrial fibrillation: can it be as easy as CC to ABC?